Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 105


Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee.

Palmer J, McCune JS, Perales MA, Marks D, Bubalo J, Mohty M, Wingard JR, Paci A, Hassan M, Bredeson C, Pidala J, Shah N, Shaughnessy P, Majhail N, Schriber J, Savani BN, Carpenter PA.

Biol Blood Marrow Transplant. 2016 Nov;22(11):1915-1925. doi: 10.1016/j.bbmt.2016.07.013. Epub 2016 Jul 29. Review.


Tbo-Filgrastim versus Filgrastim during Mobilization and Neutrophil Engraftment for Autologous Stem Cell Transplantation.

Elayan MM, Horowitz JG, Magraner JM, Shaughnessy PJ, Bachier C.

Biol Blood Marrow Transplant. 2015 Nov;21(11):1921-5. doi: 10.1016/j.bbmt.2015.05.024. Epub 2015 May 30.


Treatment of Acquired von Willebrand Syndrome and Prevention of Bleeding Postautologous Stem Cell Transplant during Severe Pancytopenia with IVIG.

Zoghi B, Shaughnessy P, Lyons RM, Helmer R 3rd, Bachier C, LeMaistre CF.

Case Rep Hematol. 2015;2015:809313. doi: 10.1155/2015/809313. Epub 2015 Apr 2.


Convergence of Parkin, PINK1, and α-Synuclein on Stress-induced Mitochondrial Morphological Remodeling.

Norris KL, Hao R, Chen LF, Lai CH, Kapur M, Shaughnessy PJ, Chou D, Yan J, Taylor JP, Engelender S, West AE, Lim KL, Yao TP.

J Biol Chem. 2015 May 29;290(22):13862-74. doi: 10.1074/jbc.M114.634063. Epub 2015 Apr 10.


Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation.

Shah N, Callander N, Ganguly S, Gul Z, Hamadani M, Costa L, Sengsayadeth S, Abidi M, Hari P, Mohty M, Chen YB, Koreth J, Landau H, Lazarus H, Leather H, Majhail N, Nath R, Osman K, Perales MA, Schriber J, Shaughnessy P, Vesole D, Vij R, Wingard J, Giralt S, Savani BN; American Society for Blood and Marrow Transplantation.

Biol Blood Marrow Transplant. 2015 Jul;21(7):1155-66. doi: 10.1016/j.bbmt.2015.03.002. Epub 2015 Mar 11. Review.


Safety and efficacy of targeted-dose busulfan and bortezomib as a conditioning regimen for patients with relapsed multiple myeloma undergoing a second autologous blood progenitor cell transplantation.

Freytes CO, Toro JJ, Yeh RF, Stadtmauer EA, Ratanatharathorn V, Akpek G, Sahovic E, Tricot GJ, Shaughnessy PJ, White DJ, Rodriguez TE, Solomon SR, Yu LH, Zhao C, Patil S, Armstrong E, Smith A, Elekes A, Kato K, Reece DE.

Biol Blood Marrow Transplant. 2014 Dec;20(12):1949-57. doi: 10.1016/j.bbmt.2014.08.007. Epub 2014 Aug 16.


Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation.

Duong HK, Savani BN, Copelan E, Devine S, Costa LJ, Wingard JR, Shaughnessy P, Majhail N, Perales MA, Cutler CS, Bensinger W, Litzow MR, Mohty M, Champlin RE, Leather H, Giralt S, Carpenter PA.

Biol Blood Marrow Transplant. 2014 Sep;20(9):1262-73. doi: 10.1016/j.bbmt.2014.05.003. Epub 2014 May 9.


Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee.

Bubalo J, Carpenter PA, Majhail N, Perales MA, Marks DI, Shaughnessy P, Pidala J, Leather HL, Wingard J, Savani BN; American Society for Blood and Marrow Transplantation practice guideline committee.

Biol Blood Marrow Transplant. 2014 May;20(5):600-16. doi: 10.1016/j.bbmt.2014.01.019. Epub 2014 Jan 23. Review.


Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations.

Giralt S, Costa L, Schriber J, Dipersio J, Maziarz R, McCarty J, Shaughnessy P, Snyder E, Bensinger W, Copelan E, Hosing C, Negrin R, Petersen FB, Rondelli D, Soiffer R, Leather H, Pazzalia A, Devine S.

Biol Blood Marrow Transplant. 2014 Mar;20(3):295-308. doi: 10.1016/j.bbmt.2013.10.013. Epub 2013 Oct 17. Review.


Outcomes and costs of autologous stem cell mobilization with chemotherapy plus G-CSF vs G-CSF alone.

Sung AD, Grima DT, Bernard LM, Brown S, Carrum G, Holmberg L, Horwitz ME, Liesveld JL, Kanda J, McClune B, Shaughnessy P, Tricot GJ, Chao NJ.

Bone Marrow Transplant. 2013 Nov;48(11):1444-9. doi: 10.1038/bmt.2013.80. Epub 2013 Jun 10.


Pharmacoeconomics of hematopoietic stem cell mobilization: an overview of current evidence and gaps in the literature.

Shaughnessy P, Chao N, Shapiro J, Walters K, McCarty J, Abhyankar S, Shayani S, Helmons P, Leather H, Pazzalia A, Pickard S.

Biol Blood Marrow Transplant. 2013 Sep;19(9):1301-9. doi: 10.1016/j.bbmt.2013.05.008. Epub 2013 May 14. Review.


Plerixafor and G-CSF for autologous stem cell mobilization in patients with NHL, Hodgkin's lymphoma and multiple myeloma: results from the expanded access program.

Shaughnessy P, Uberti J, Devine S, Maziarz RT, Vose J, Micallef I, Jacobsen E, McCarty J, Stiff P, Artz A, Ball ED, Berryman R, Dugan M, Joyce R, Hsu FJ, Johns D, McSweeney P.

Bone Marrow Transplant. 2013 Jun;48(6):777-81. doi: 10.1038/bmt.2012.219. Epub 2012 Nov 26.


Peripheral-blood stem cells versus bone marrow from unrelated donors.

Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR, Cutler CS, Westervelt P, Woolfrey A, Couban S, Ehninger G, Johnston L, Maziarz RT, Pulsipher MA, Porter DL, Mineishi S, McCarty JM, Khan SP, Anderlini P, Bensinger WI, Leitman SF, Rowley SD, Bredeson C, Carter SL, Horowitz MM, Confer DL; Blood and Marrow Transplant Clinical Trials Network.

N Engl J Med. 2012 Oct 18;367(16):1487-96. doi: 10.1056/NEJMoa1203517.


Evaluation of services for children with complex needs: mapping service provision in one NHS Trust.

Brooks F, Bloomfield L, Offredy M, Shaughnessy P.

Prim Health Care Res Dev. 2013 Jan;14(1):52-62. doi: 10.1017/S1463423612000217. Epub 2012 Jul 12.


G-CSF plus plerixafor (Mozobil) to mobilize hematopoietic stem cells in patients with thrombocytopenia or leukopenia prior to auto-SCT.

Micallef IN, Jacobsen ED, Shaughnessy P, Gandhi PJ, Calandra G, van Rhee F, Uberti J.

Bone Marrow Transplant. 2013 Feb;48(2):303-4. doi: 10.1038/bmt.2012.125. Epub 2012 Jul 9. No abstract available.


First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation.

Martin PJ, Rizzo JD, Wingard JR, Ballen K, Curtin PT, Cutler C, Litzow MR, Nieto Y, Savani BN, Schriber JR, Shaughnessy PJ, Wall DA, Carpenter PA.

Biol Blood Marrow Transplant. 2012 Aug;18(8):1150-63. doi: 10.1016/j.bbmt.2012.04.005. Epub 2012 Apr 14. Review.


High white blood cell concentration in the peripheral blood stem cell product can induce seizures during infusion of autologous peripheral blood stem cells.

Bachier C, Potter J, Potter G, Sugay R, Shaughnessy P, Chan K, Jude V, Madden R, LeMaistre CF.

Biol Blood Marrow Transplant. 2012 Jul;18(7):1055-60. doi: 10.1016/j.bbmt.2011.12.500. Epub 2011 Dec 16.


Once daily busulfan cyclophosphamide is well tolerated and effective as a preparative regimen for allogeneic hematopoietic stem cell transplant.

LeMaistre JA, Bachier C, Smith B, LeMaistre CF, Shaughnessy PJ.

J Oncol Pharm Pract. 2012 Mar;18(1):17-22. doi: 10.1177/1078155210392616. Epub 2011 Jan 12.


Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide.

Shaughnessy P, Islas-Ohlmayer M, Murphy J, Hougham M, MacPherson J, Winkler K, Silva M, Steinberg M, Matous J, Selvey S, Maris M, McSweeney PA.

Biol Blood Marrow Transplant. 2011 May;17(5):729-36. doi: 10.1016/j.bbmt.2010.08.018. Epub 2010 Oct 14.


Comparison of short-term response and long-term outcomes after initial systemic treatment of chronic graft-versus-host disease.

Martin PJ, Storer BE, Carpenter PA, Couriel DR, Flowers ME, Gupta V, Hsu JW, Jagasia M, Kitko CL, Maziarz RT, Rowley SD, Shaughnessy PJ, van Besien K, Weisdorf D, Lee SJ.

Biol Blood Marrow Transplant. 2011 Jan;17(1):124-32. doi: 10.1016/j.bbmt.2010.06.018. Epub 2010 Jun 30.

Supplemental Content

Loading ...
Support Center